increas
bodi
evid
suggest
exist
extens
correl
inflamm
coagul
wherebi
inflamm
lead
coagul
coagul
also
affect
inflammatori
activ
keller
et
al
opal
esmon
levi
et
al
van
der
poll
levi
inflamm
impact
initi
propag
inhibitori
phase
blood
coagul
opal
viral
bacteri
infect
actual
lead
thrombot
well
hemorrhag
complic
pathogen
well
inflammatori
cell
mediat
induc
express
tissu
factor
monocyt
endotheli
cell
surfac
tissu
factor
major
activ
coagul
van
der
poll
et
al
direct
indirect
activ
endothelium
virus
pathogen
may
result
alter
coagul
fibrinolyt
system
van
gorp
et
al
normal
coagul
balanc
procoagul
natur
anticoagul
mechan
regul
activ
coagul
part
host
defenc
infecti
agent
opal
inflamm
may
lead
alter
coagul
result
imbal
anticoagul
state
clinic
pictur
alter
coagul
sever
viral
infect
manifest
bleed
hemorrhag
thrombosi
exagger
respons
may
even
lead
dissemin
intravascular
coagul
format
microvascular
thrombi
variou
organ
levi
dissemin
intravascular
coagul
contribut
multipl
organ
failur
associ
high
mortal
bacteri
nonbacteri
diseas
levi
et
al
levi
syndrom
associ
bacteri
viral
infect
hemolyt
uraem
syndrom
idiopath
thrombocytopen
purpura
thrombot
thrombocytopen
purpura
van
gorp
et
al
yet
clear
virus
caus
hemorrhag
eg
ebola
other
associ
thrombosi
eg
cytomegaloviru
yet
other
show
complic
eg
varicella
zoster
viru
miller
stephan
uthman
gharavi
geisbert
jahrl
squizzato
et
al
addit
bleed
complic
hemorrhag
virus
vari
sever
minor
bleed
complic
form
dengu
sever
bleed
ebola
marburg
mani
viral
infect
target
therapi
avail
support
care
provid
mani
mild
case
treatment
may
even
necessari
howev
improv
therapi
support
care
complic
viral
infect
better
understand
need
pathogenesi
bleed
thrombot
complic
due
viral
infect
review
briefli
outlin
coagul
cascad
gener
well
interact
coagul
cascad
cytokin
releas
viral
infect
subsequ
clinic
pictur
coagul
alter
seen
viral
diseas
review
final
explan
given
presum
mechan
virus
influenc
hemostasi
influenc
viral
infect
atherosclerosi
atherothrombosi
discuss
procoagul
prothrombot
two
term
use
literatur
indic
thing
tendenc
develop
thrombosi
review
term
procoagul
use
refer
chang
coagul
marker
determin
laboratori
prothrombot
state
indic
clinic
risk
situat
gener
speak
viral
infect
sever
procoagul
marker
elev
indic
coagul
system
activ
procoagul
state
defin
number
alter
blood
firstli
increas
level
clot
factor
eg
factor
viii
factor
xi
solubl
tissu
factor
von
willebrand
factor
secondli
regulatori
system
defici
indic
decreas
level
natur
anticoagul
protein
c
protein
antithrombin
tissu
factor
pathway
inhibitor
furthermor
marker
thrombin
gener
prothrombin
fragment
complex
platelet
activ
fibrin
degrad
fibrinolysi
eg
complex
also
increas
mani
studi
carri
influenc
inflamm
pro
inflammatori
cytokin
coagul
system
activ
coagul
cascad
inflamm
result
stimul
coagul
synthesi
decreas
synthesi
suppress
fibrinolysi
lipinski
et
al
net
result
increas
express
tissu
factor
lead
activ
extrins
coagul
pathway
togeth
downregul
activ
protein
c
inhibit
fibrinolysi
petaja
cytokin
like
known
increas
product
von
willebrand
factor
may
result
platelet
activ
upregul
tissu
factor
express
via
activ
receptor
monocyt
microparticl
endotheli
cell
opal
levi
et
al
schouten
et
al
furthermor
gener
activ
protein
c
also
decreas
due
lower
express
thrombomodulin
surfac
endotheli
cell
act
cofactor
activ
protein
c
one
hand
anticoagul
decreas
hand
upregul
plasminogen
activ
abl
block
activ
plasminogen
thu
creat
decreas
breakdown
fibrin
clot
keller
et
al
opal
schouten
et
al
gener
thrombin
gener
increas
due
inflamm
result
procoagul
state
clot
cascad
levi
et
al
previous
describ
clinic
pictur
vascular
complic
viral
infect
consist
thrombosi
andor
hemorrhag
tabl
show
overview
clinic
patholog
laboratori
abnorm
seen
alter
hemostasi
due
viral
infect
common
virus
known
caus
alter
hemostasi
discuss
main
focu
respiratori
virus
hiv
herp
virus
hemorrhag
fever
virus
respiratori
tract
infect
increas
risk
deep
venou
thrombosi
possibl
pulmonari
embol
smeeth
et
al
patient
infect
influenza
viru
known
suffer
dissemin
intravascular
coagul
pulmonari
microembol
davison
et
al
harm
et
al
recent
outbreak
influenza
swine
flu
thrombot
hemorrhag
complic
report
deep
venou
thrombosi
pulmonari
embol
pulmonari
hemorrhag
hemoptysi
hematemesi
petechi
rash
one
case
dissemin
petechi
brain
hemorrhag
agarw
et
al
et
al
adalja
gilbert
et
al
harm
et
al
mauad
et
al
mukhopadhyay
et
al
kassi
venkata
et
al
bunc
et
al
calor
et
al
frequent
signific
present
report
complic
direct
effect
uncertain
sever
influenza
case
intraren
fibrin
deposit
found
lead
renal
failur
highli
pathogen
avian
influenza
infect
result
dissemin
intravascular
coagul
pulmonari
hemorrhag
thrombocytopenia
sever
patient
wiwanitkit
one
studi
report
number
children
develop
hematemesi
influenza
infect
armstrong
et
al
frequent
influenza
infect
lead
clinic
relev
thrombot
diseas
yet
establish
rsv
adenoviru
known
caus
clinic
relev
vascular
complic
rel
recent
outbreak
sar
novel
coronaviru
show
signific
morbid
mortal
clinic
pictur
pertain
coagul
consist
vascular
endotheli
damag
pulmonari
vessel
dissemin
intravascular
coagul
deep
venou
thrombosi
pulmonari
thromboemboli
result
pulmonari
infarct
lee
et
al
chong
et
al
hwang
et
al
associ
cmv
infect
thromboembol
diseas
establish
anim
persoon
et
al
human
mostli
immunocompromis
patient
maslo
et
al
kazori
et
al
sengul
et
al
lijfer
et
al
report
made
thrombot
event
cmv
infect
immunocompet
subject
well
abgueguen
et
al
youd
et
al
squizzato
et
al
delbo
et
al
sever
case
addit
procoagul
risk
factor
present
protein
c
defici
factor
v
leiden
mutat
heterozyg
prothrombin
mutat
bauduer
et
al
fridlend
et
al
lijfer
et
al
hepat
c
infect
hcv
associ
thrombosi
hcv
observ
frequent
patient
suffer
liver
cirrhosi
splanchnic
venou
thrombosi
thrombophleb
without
thrombosi
indic
hcv
infect
may
contribut
venou
thrombosi
squizzato
gerd
violi
et
al
thrombocytopenia
common
hematolog
complic
observ
document
number
rang
sever
thrombocytopenia
correl
count
bleed
complic
rare
hiv
associ
thrombocytopenia
platelet
count
remain
low
long
time
passo
et
al
thrombot
thrombocytopen
purpura
patient
rel
common
introduct
effect
antiretrovir
therapi
sinc
introduct
treatment
thrombot
thrombocytopen
purpura
rare
condit
associ
advanc
hiv
diseas
becker
et
al
cardiovascular
complic
report
acut
chronic
hiv
infect
et
al
overal
risk
venou
thrombot
diseas
patient
may
two
ten
time
high
healthi
individu
klein
et
al
et
al
use
proteas
inhibitor
link
venou
well
arteri
thrombot
event
klein
et
al
et
al
strong
indic
incid
rate
vascular
complic
antiretrovir
era
increas
klein
et
al
wherea
hiv
respiratori
virus
thrombot
clinic
complic
mani
acut
viral
infect
may
result
bleed
often
pathogen
classifi
hemorrhag
fever
virus
devast
member
filovirida
ebola
marburg
arenavirus
lassa
fever
south
american
hemorrhag
fever
bleed
often
occur
variou
mucou
membran
togeth
easi
bruis
persist
bleed
venapunctur
massiv
bleed
may
occur
tract
andor
kortepet
et
al
bleed
complic
frequent
sever
form
infect
correl
case
fatal
rate
bleed
thought
consequ
imbalanc
coagul
cascad
sometim
result
dissemin
intravascular
coagul
seen
hantaviru
ebola
marburg
hemorrhag
fever
dengu
infect
geisbert
jahrl
bray
lain
et
al
bleed
manifest
promin
ebola
hantaviru
hemorrhag
fever
geisbert
jahrl
thrombocytopenia
consist
found
among
viral
hemorrhag
fever
infect
well
decreas
platelet
function
thrombocytopathia
geisbert
jahrl
known
vascular
complic
arenavir
infect
addit
mucos
bleed
sever
pericardi
effus
latter
also
consequ
vascular
dysfunct
dissemin
intravascular
coagul
seem
play
role
arenavir
infect
peter
et
al
richmond
baglol
hantavirus
circul
europ
asia
associ
hemorrhag
fever
renal
syndrom
hfr
milder
nephropathia
epidemica
ne
variant
khaiboullina
et
al
jonsson
et
al
hallmark
symptom
hfr
acut
kidney
failur
alter
hemostasi
rang
mild
thrombocytopenia
dissemin
intravascular
coagul
sundberg
et
al
first
less
sever
bleed
complic
like
epistaxi
conjunctiv
bleed
hematuria
petechia
mucos
bleed
occur
later
phase
gastrointestin
pleural
bleed
report
sever
hfr
less
common
hemorrhag
event
right
atrial
hemorrhag
chun
godfrey
spleen
hemorrhag
alexeyev
et
al
pituitari
gland
hemorrhag
result
endocrin
disturb
even
panhypopituitar
suh
et
al
pekic
et
al
hantavirus
circul
north
south
america
caus
hantaviru
cardiopulmonari
syndrom
result
acut
respiratori
distress
thrombocytopenia
howev
bleed
disord
play
less
signific
role
patholog
diseas
dengu
viru
one
widespread
virus
worldwid
annual
infect
rate
around
million
use
subdivid
dengu
fever
dengu
hemorrhag
fever
dengu
shock
syndrom
recent
classif
break
dengu
patient
dengu
case
without
warn
sign
sever
dengu
case
latter
patient
present
either
shock
respiratori
distress
sever
organ
impair
sever
bleed
van
de
weg
et
al
occurr
sever
dengu
bleed
sign
shock
differ
world
therefor
assum
interact
host
viru
vector
environ
defin
clinic
present
outcom
although
thrombocytopenia
well
document
dengu
infect
sosothikul
et
al
associ
establish
presenc
activ
bleed
degre
thrombocytopenia
admiss
bleed
symptom
dengu
case
often
start
petechia
bleed
mucou
membran
epistaxi
sever
case
typic
larg
gastrointestin
bleed
may
occur
recent
outbreak
novel
bunyaviru
caus
clinic
syndrom
describ
sever
fever
thrombocytopenia
syndrom
patient
rapidli
develop
thrombocytopenia
accompani
multipl
organ
dysfunct
gastrointestin
complaint
case
fatal
rate
estim
around
zhang
et
al
data
experiment
human
studi
reveal
complex
interact
infecti
pathogen
cytokin
effector
cell
coagul
system
review
discuss
exist
evid
pathogenesi
abnorm
hemostasi
viral
infect
regard
primari
hemostasi
secondari
hemostasi
fibrinolysi
antiphospholipid
antibodi
discuss
separ
platelet
key
player
primari
hemostasi
format
platelet
plug
reduc
platelet
function
well
diminish
product
destruct
platelet
phenomenon
sever
viral
infect
thrombocytopenia
often
occur
hemorrhag
viral
infect
case
thrombocytopenia
caus
autoimmun
antibodi
platelet
propos
mechan
includ
increas
adher
activ
platelet
lead
consumpt
platelet
infect
bone
marrow
directli
affect
megakaryocyt
thu
product
platelet
thrombocytopenia
caus
autoantibodi
describ
sar
influenza
chronic
parvoviru
herp
viru
cmv
vzv
epstein
barr
viru
hiv
hepat
viru
hepat
c
viru
infect
whitak
et
al
kahan
et
al
kazatchkin
et
al
mayer
beardsley
neau
et
al
rand
wright
scheurlen
et
al
sainokami
et
al
yang
et
al
panzer
et
al
passo
et
al
autoantibodi
identifi
sever
viral
infect
target
usual
one
surfac
glycoprotein
gpiibiiia
gpibix
gpv
possibl
cross
reactiv
antibodi
viru
platelet
mayer
beardsley
tanaka
et
al
hiv
platelet
bound
via
platelet
glycoprotein
iiia
integrin
passo
et
al
whether
platelet
destruct
viral
hepat
caus
glycoprotein
antibodi
immun
complex
bound
platelet
surfac
combin
remain
uncertain
doi
et
al
weksler
secondari
dengu
viru
infect
platelet
apoptosi
seem
enhanc
result
increas
platelet
clearanc
alonzo
et
al
probabl
present
viral
infect
lead
system
inflammatori
respons
platelet
may
serv
carrier
viral
infect
damag
partial
destroy
terada
et
al
platelet
consumpt
due
mechan
document
influenza
sar
hantaviru
adenoviru
infect
lee
rand
wright
yang
et
al
othman
et
al
endotheli
cell
seem
bind
quiescent
platelet
via
integrin
depend
mechan
cellular
receptor
hantaviru
gavrilovskaya
et
al
may
result
decreas
number
platelet
thrombocytopenia
also
decreas
function
increas
vascular
permeabl
furthermor
hemorrhag
fever
renal
syndrom
patient
china
intens
receptor
also
known
flow
platelet
correl
sever
diseas
liu
et
al
platelet
deriv
patient
infect
lassa
fever
depress
capac
platelet
aggreg
cummin
et
al
robert
et
al
richmond
baglol
plasma
lassa
fever
patient
show
inhibit
platelet
aggreg
inhibit
found
lassa
fever
patient
hemorrhag
without
hemorrhag
plasma
sampl
lassa
fever
patient
mix
control
plasma
mark
inhibit
aggreg
observ
find
indic
platelet
dysfunct
may
play
import
role
bleed
characterist
diseas
cummin
et
al
robert
et
al
howev
decreas
fibrinogen
concentr
may
also
play
role
explain
phenomenon
furthermor
influenza
rhinoviru
virus
stimul
product
bouwman
et
al
complex
interplay
othman
et
al
virus
bind
platelet
activ
lead
rapid
exposur
platelet
surfac
turn
trigger
format
aggreg
subsequ
endotheli
cell
activ
demonstr
increas
vascular
cell
adhes
molecul
von
willebrand
factor
endotheli
microparticl
reduc
product
platelet
observ
sar
hcv
hiv
hantaviru
junin
hemorrhag
fever
infect
caus
direct
infect
hemapoiet
stemprogenitor
cell
megakaryocyt
carbal
et
al
li
et
al
yang
et
al
luttek
et
al
passo
et
al
exampl
pathogen
hantavirus
invad
subsequ
replic
megakaryocyt
lead
upregul
human
leukocyt
antigen
hla
class
molecul
target
structur
cytotox
vitro
kill
infect
megakaryocyt
hypothet
lead
decreas
platelet
product
could
also
explain
corticosteroid
treatment
increas
platelet
count
inhibit
cellular
immun
respons
patient
dunst
et
al
seitsonen
et
al
addit
impair
thrombopoietin
product
primari
cytokin
govern
megakaryocyt
matur
platelet
format
kaushanski
present
hcv
hepatocellular
damag
weksler
reduc
platelet
product
alway
caus
infect
sometim
medic
therapi
exampl
pegyl
interferon
treatment
hcv
antiretrovir
therapi
hiv
kowdley
passo
et
al
final
hypersplen
sequestr
platelet
due
portal
hypertens
present
chronic
hepat
weksler
viral
infect
alter
level
varieti
coagul
protein
may
consequ
lead
prothrombot
state
could
result
thrombot
event
procoagul
state
may
present
increas
level
coagul
protein
like
fibrinogen
horan
et
al
factor
vii
woodhous
et
al
presenc
elev
level
factor
viii
risk
factor
found
chronic
hbv
hcv
patient
papatheodoridi
et
al
laboratori
studi
shown
herp
virus
facilit
factor
xa
gener
inact
precursor
factor
x
factor
viiviia
calcium
ion
present
sutherland
et
al
rais
coagul
marker
also
found
anim
human
tissu
increas
number
intravascular
thrombi
fibrin
deposit
lung
found
case
influenza
avian
influenza
sar
infect
may
well
result
dissemin
intravascular
coagul
microthrombosi
hwang
et
al
keller
et
al
muramoto
et
al
sar
infect
pulmonari
infarct
observ
hwang
et
al
fibrin
deposit
also
found
tissu
primat
infect
ebola
viru
geisbert
et
al
b
contrast
activ
coagul
system
describ
activ
factor
ii
v
vii
viii
ix
x
factor
xii
decreas
dengu
hantaviru
infect
factor
ii
v
viii
ix
x
seem
decreas
lee
howev
result
dengu
research
inconclus
mairuhu
et
al
decreas
level
coagul
factor
associ
hemorrhag
might
due
consumpt
loss
factor
convalesc
phase
dhf
factor
viii
level
factor
viia
level
increas
compar
dengu
fever
df
sosothikul
et
al
elev
level
factor
complex
found
patient
dhf
indic
activ
coagul
van
gorp
et
al
macaqu
infect
ebola
viru
show
decreas
level
factor
viia
geisbert
et
al
prolong
clot
time
report
sever
viral
infect
hemorrhag
viral
infect
hantaviru
vzv
infect
canpolat
bakir
kurugol
et
al
lain
et
al
activ
coagul
system
result
elev
level
sever
system
coagul
marker
increas
level
prothrombin
fragment
complex
andor
complex
found
respiratori
tract
infect
influenza
sar
hiv
hcv
vzv
virus
bray
et
al
canpolat
bakir
et
al
feffer
et
al
geisbert
et
al
b
keller
et
al
kurugol
et
al
lain
et
al
lee
et
al
mairuhu
et
al
schouten
et
al
van
gorp
et
al
violi
et
al
wu
et
al
patient
hcv
infect
level
prothrombin
fragment
elev
significantli
violi
et
al
increas
ratio
indic
balanc
shift
procoagul
state
found
dengu
patient
associ
advers
clinic
outcom
van
gorp
et
al
fatal
case
ebola
infect
show
higher
level
fibrin
degrad
product
acut
phase
diseas
bray
et
al
rollin
et
al
level
coagul
product
correl
death
dissemin
intravascular
coagul
may
therefor
earli
import
compon
ebola
infect
bray
et
al
rollin
et
al
conclud
gener
speak
hemorrhag
virus
may
lead
activ
coagul
system
acut
phase
ultim
lead
consumpt
loss
clot
factor
microthrombi
caus
organ
failur
endotheli
cell
dysfunct
bleed
phenotyp
howev
sever
issu
relationship
viral
infect
coagul
system
remain
unknown
exampl
gap
knowledg
effect
viral
hemorrhag
fever
coagul
marker
data
come
studi
dengu
viru
infect
furthermor
limit
data
exist
durat
procoagul
state
viral
infect
exampl
elev
level
procoagul
protein
viral
respiratori
tract
infect
return
baselin
two
week
keller
et
al
studi
children
dengu
shock
syndrom
dss
fibrinogen
level
decreas
significantli
two
day
hospit
admiss
return
normal
within
month
will
et
al
sever
viral
infect
lead
defici
natur
anticoagul
protein
c
protein
antithrombin
heparin
cofactor
ii
well
known
defici
associ
increas
risk
thrombosi
defici
report
respiratori
tract
infect
gener
vzv
hiv
hbv
hcv
hantaviru
dss
ebola
viru
infect
bissuel
et
al
canpolat
bakir
et
al
erb
et
al
geisbert
et
al
kaba
et
al
kurugol
et
al
lain
et
al
papatheodoridi
et
al
will
et
al
probabl
defici
mechan
includ
autoantibodi
protein
c
protein
antithrombin
describ
vzv
infect
josephson
et
al
van
ommen
et
al
well
leakag
protein
endothelium
capillari
dengu
shock
will
et
al
consumpt
natur
anticoagul
esmon
sosothikul
et
al
lain
et
al
anoth
underli
mechan
could
decreas
synthesi
clot
factor
liver
chronic
viral
hepat
degre
antithrombin
protein
c
defici
found
strongli
associ
advanc
fibrosi
liver
papatheodoridi
et
al
increas
local
product
thrombomodulin
may
anticoagul
effect
dahlback
thrombomodulin
express
increas
surfac
sinusoid
endotheli
cell
chronic
hepat
b
c
patient
zeniya
et
al
solubl
thrombomodulin
level
also
increas
patient
sar
sever
dengu
infect
will
et
al
liu
et
al
sosothikul
et
al
furthermor
dengu
viru
promot
express
thrombomodulin
cultur
endotheli
cell
jiang
et
al
circul
solubl
thrombomodulin
may
reflect
endotheli
cell
activ
howev
thrombomodulin
activ
bound
endothelium
schouten
et
al
impair
fibrinolysi
hypofibrinolyt
state
thu
elev
risk
thrombosi
report
sever
viral
infect
two
mechan
consid
firstli
increas
level
plasminogen
activ
found
influenza
sar
vzv
cmv
dengu
hiv
infect
woodroff
kuan
kurugol
et
al
koppel
et
al
will
et
al
klein
et
al
keller
et
al
wu
et
al
sosothikul
et
al
schouten
et
al
hiv
infect
elev
plasminogen
activ
level
shown
relat
metabol
syndrom
use
proteas
inhibitor
part
antiretrovir
therapi
koppel
et
al
secondli
plasminogen
defici
present
patient
chronic
viral
hepat
papatheodoridi
et
al
dengu
viru
infect
associ
hyperfibrinolyt
state
due
increas
level
activ
activ
result
increas
breakdown
fibrin
strand
thu
elev
risk
hemorrhag
howev
increas
level
plasminogen
activ
also
found
dengu
viru
infect
correl
diseas
sever
huang
et
al
van
gorp
et
al
will
et
al
mairuhu
et
al
jiang
et
al
sosothikul
et
al
hantaviru
infect
enhanc
fibrinolysi
could
compens
increas
coagul
activ
contribut
clinic
recoveri
explain
bleed
complic
seen
hantaviru
case
lain
et
al
addit
increas
plasma
concentr
activ
solubl
thrombomodulin
found
sar
infect
liu
et
al
howev
assay
quantifi
activ
plasminogen
activ
use
measur
circul
protein
protein
complex
make
hard
identifi
actual
plasma
level
patient
infect
hemorrhag
fever
dengu
viru
fibrinolysi
inhibitor
activ
decreas
may
contribut
imbal
fibrinolysi
mairuhu
et
al
sonmez
et
al
sosothikul
et
al
decreas
fibrinolysi
inhibitor
activ
may
due
liver
dysfunct
infect
sonmez
et
al
may
also
suggest
consumpt
inhibitor
excess
thrombin
format
mairuhu
et
al
relationship
antiphospholipid
antibodi
thrombosi
infect
fulli
clear
antibodi
phospholipid
acut
infect
divers
group
autoantibodi
protein
bound
phospholipid
remain
plasma
short
period
relat
clinic
thrombosi
de
groot
urbanu
howev
antiphospholipid
antibodi
direct
plasma
protein
associ
arteri
venou
thrombosi
pregnanc
complic
et
al
asherson
et
al
espinosa
et
al
antiphospholipid
antibodi
associ
infect
parvoviru
sever
herp
virus
cmv
ebv
vzv
hav
hbv
hcv
hiv
yamazaki
et
al
prieto
et
al
violi
et
al
kurugol
et
al
ertem
et
al
uthman
gharavi
youd
et
al
yust
prieto
cervera
asherson
van
hal
et
al
et
al
sene
et
al
antiphospholipid
antibodi
frequent
found
patient
chronic
hcv
infect
implic
thrombosi
also
thrombocytopenia
prieto
et
al
suggest
antiphospholipid
antibodi
might
particip
process
fibrosi
promot
thrombosi
small
intrahepat
vessel
whether
antibodi
contribut
clinic
import
thrombot
event
infect
remain
controversi
prieto
et
al
mangia
et
al
harada
et
al
josephson
et
al
cervera
asherson
sene
et
al
gharavi
et
al
shown
immun
peptid
deriv
cytomegaloviru
induc
lupu
anticoagul
activ
result
thrombot
complic
presenc
antibodi
report
cmv
patient
present
thrombosi
delbo
et
al
de
groot
urbanu
review
avail
literatur
becom
clear
although
much
known
pathophysiolog
mechan
behind
associ
viral
infect
alter
coagul
cascad
mani
question
still
remain
clear
exampl
virus
strong
influenc
coagul
associ
thrombot
complic
bleed
viral
infect
effect
limit
complex
interplay
host
viru
virul
vector
environ
infect
pressur
commun
defin
clinic
present
outcom
might
explain
diverg
clinic
present
viral
infect
differ
part
world
furthermor
differ
clinic
present
could
also
explain
divers
tropism
virus
monocyt
endotheli
cell
exampl
alway
clear
whether
viru
exert
effect
direct
infect
target
cell
antibodi
via
inflammatori
mediat
addit
inherit
host
factor
also
play
role
diseas
sever
implement
specif
therapeut
intervent
crucial
know
hemostat
balanc
individu
affect
cours
infect
extrem
difficult
determin
particularli
acut
infect
main
reason
theoret
promis
intervent
activ
protein
c
less
success
disappoint
even
clinic
practic
coagul
disord
vari
among
viral
hemorrhag
fever
coagul
fibrinolysi
activ
degre
activ
coagul
system
influenc
abil
host
effect
balanc
counteract
effect
geisbert
jahrl
quit
possibl
major
similar
mechan
differ
viral
infect
interact
coagul
pathway
even
though
studi
interact
sever
viral
infect
coagul
perform
differ
method
focus
variou
element
coagul
system
seem
evid
virus
interact
coagul
common
way
specif
featur
relat
specif
viru
furthermor
research
alter
coagul
perform
virus
cmv
exampl
other
conceiv
less
preval
viral
infect
exert
effect
coagul
cascad
studi
lack
case
filovirus
littl
research
perform
partli
hazard
logist
difficulti
associ
collect
process
blood
sampl
remot
region
africa
outbreak
usual
occur
furthermor
data
come
vitro
studi
may
accur
reflect
situat
actual
infect
human
vivo
data
also
clear
squizzato
et
al
exampl
ebola
infect
induc
primat
although
use
determin
pathophysiolog
mechan
consid
repres
human
infect
diseas
monkey
appear
develop
rapidli
take
sever
clinic
cours
rollin
et
al
virus
yet
adequ
anim
model
effect
viral
infect
coagul
result
clinic
pictur
could
exacerb
factor
thrombophilia
host
factor
exampl
environ
ie
infect
pressur
sever
studi
shown
patient
thrombot
complic
cmv
infect
addit
thrombophil
factor
present
factor
v
leiden
mutat
prothrombin
mutat
fridlend
et
al
lijfer
et
al
possibl
patient
would
develop
thrombosi
without
thrombophilia
case
respiratori
virus
season
variat
sever
hemostat
protein
may
contribut
pronounc
effect
coagul
therefor
develop
thrombosi
document
winter
platelet
count
fibrinogen
factor
vii
plasminogen
activ
elev
woodhous
et
al
frohlich
et
al
crawford
et
al
natur
occur
season
variat
may
exist
independ
viral
infect
respiratori
virus
common
winter
suggest
combin
season
variat
viral
infect
pronounc
effect
coagul
system
result
higher
risk
thrombosi
found
risk
thrombosi
elev
first
two
week
respiratori
tract
infect
smeeth
et
al
bleed
may
result
multifactori
process
result
combin
thrombocytopenia
due
autoantibodi
consumpt
platelet
consumpt
clot
factor
local
fibrinolysi
vascular
damag
leakag
hemorrhag
virus
infect
lead
increas
anticoagul
activ
hyperfibrinolysi
partli
activ
endotheli
cell
exampl
data
dengu
viru
infect
show
increas
endotheli
cell
damag
sosothikul
et
al
conflict
data
martina
et
al
despit
increas
data
associ
viral
infect
coagul
cascad
pathophysiolog
mechan
behind
associ
yet
elucid
fulli
virus
knowledg
underli
mechan
lead
thrombosi
bleed
fundament
develop
therapeut
strategi
treatment
thrombohemorrhag
complic
given
potenti
role
tissu
factor
may
play
thrombohemorrhag
complic
viral
diseas
therapeut
intervent
tissu
factor
level
exampl
aim
one
critic
cytokin
mediat
cellular
express
may
alter
clinic
cours
infect
favour
exampl
patient
infect
dengu
pharmacolog
agent
block
tissu
factor
may
repres
import
therapeut
approach
et
al
studi
rhesu
monkey
infect
ebola
viru
treatment
recombin
inhibitor
factor
viiatissu
factor
show
prolong
surviv
time
attenu
coagul
proinflammatori
respons
geisbert
et
al
anoth
studi
rhesu
monkey
infect
ebola
viru
treatment
recombin
human
activ
protein
c
improv
chanc
surviv
significantli
hensley
et
al
therapi
reduc
coagulopathi
decreas
inflamm
viral
replic
exampl
indic
therapeut
strategi
target
coagul
cascad
seem
promis
howev
none
readi
phase
trial
mani
issu
remain
unansw
urgent
need
clinic
experiment
studi
furthermor
addit
studi
need
investig
sever
area
includ
efficaci
prophylact
lmwh
need
test
viral
pathogen
patient
thrombosi
irregular
place
portal
vein
prothrombot
intervent
patient
hemorrhag
viral
infect
proper
treatment
patient
viral
dic
summari
past
decad
world
confront
outbreak
old
new
viral
infect
often
accompani
activ
coagul
differ
level
coagul
cascad
result
venou
thrombosi
dic
microvascular
thrombosi
bleed
although
direct
interact
viru
coagul
system
occur
coagul
activ
also
indirectli
influenc
cytokin
imbal
coagul
cascad
may
result
either
procoagul
profibrinolyt
gener
speak
chronic
viral
infect
seem
associ
thrombot
complic
acut
viral
infect
associ
either
thrombot
hemorrhag
complic
howev
therapeut
antivir
option
still
limit
vaccin
often
avail
make
support
treatment
crucial
clinic
manag
often
infect
although
evid
still
limit
patient
unexplain
thrombosi
place
extrem
lung
portal
vein
exampl
describ
hav
hcv
cmv
infect
see
tabl
test
viral
pathogen
furthermor
strong
associ
sever
viral
infect
antiphospholipid
antibodi
discuss
patient
newli
found
antiphospholipid
antibodi
also
screen
viral
pathogen
take
account
local
epidemiolog
travel
histori
patient
admit
hospit
sever
viral
infect
thrombosi
prophylaxi
low
heparin
start
unless
increas
risk
bleed
furthermor
patient
bedbound
admit
hospit
also
consid
treatment
low
heparin
mild
thrombocytopenia
platelet
count
low
heparin
contraind
insuffici
studi
made
field
support
recommend
guidelin
american
colleg
chest
physician
accp
consult
geert
et
al
eikelboom
et
al
patient
bleed
complic
without
system
inflammatori
respons
syndrom
sepsi
due
viral
infect
receiv
prompt
standard
support
care
fluid
resuscit
ventilatori
support
exampl
state
treatment
guidelin
sever
sepsi
septic
shock
delling
et
al
sever
bleed
complic
administr
plasma
product
platelet
may
necessari
intervent
antithrombin
investig
suffici
might
use
individu
case
recombin
activ
protein
c
prove
use
certain
case
larger
trial
show
benefici
effect
treatment
longer
avail
furthermor
novel
anticoagul
block
thrombin
factor
xa
might
high
potenti
howev
occurr
bleed
complic
problem
studi
investig
valu
therapeut
agent
requir
especi
dengu
viru
infect
given
preval
viru
caus
hemorrhag
fever
therapeut
intervent
tissu
factor
pathway
seem
promis
support
evid
still
limit
yet
near
larg
human
tiral
research
focu
first
develop
antivir
agent
vaccin
better
understand
pathogenesi
coagul
disord
infect
urgent
need
improv
support
care
